Evidence map›Paper›PMID 27188843›Full record

ArticleNature communications2016

Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells.

Kerstin Göbel, Susann Pankratz, Chloi-Magdalini Asaridou, Alexander M Herrmann, Stefan Bittner, Monika Merker, Tobias Ruck, Sarah Glumm, Friederike Langhauser, Peter Kraft and 22 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 3 pooled it
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 3 syntheses or guidelines pooled it, 122 citations in OpenAlex.

  1. Factor XII-A New Therapeutic Target? A Systematic Review.International journal of molecular sciences · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Plasma proteomic profiles of UK Biobank participants with multiple sclerosis.Annals of clinical and translational neurology · 2024
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Triazol-1-yl Benzamides Promote Anticoagulant ActivityCardiovascular & hematological agents in medicinal chemistry · 2023
    Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 12 institutions in 2 countries.

Kerstin GöbelDepartment of Neurology, Clinic of Neurology and Institute for Translational Neurology, University of Münster, 48149 Münster, Germany.
Susann PankratzDepartment of Neurology, Clinic of Neurology and Institute for Translational Neurology, University of Münster, 48149 Münster, Germany.
Chloi-Magdalini AsaridouDepartment of Neurology, Clinic of Neurology and Institute for Translational Neurology, University of Münster, 48149 Münster, Germany.
Alexander M HerrmannDepartment of Neurology, Clinic of Neurology and Institute for Translational Neurology, University of Münster, 48149 Münster, Germany.
Stefan BittnerDepartment of Neurology, Clinic of Neurology and Institute for Translational Neurology, University of Münster, 48149 Münster, Germany.
Monika MerkerDepartment of Neurology, Clinic of Neurology and Institute for Translational Neurology, University of Münster, 48149 Münster, Germany.
Tobias RuckDepartment of Neurology, Clinic of Neurology and Institute for Translational Neurology, University of Münster, 48149 Münster, Germany.
Sarah GlummDepartment of Neurology, Clinic of Neurology and Institute for Translational Neurology, University of Münster, 48149 Münster, Germany.
Friederike LanghauserDepartment of Neurology, University Hospital Würzburg, 97080 Würzburg, Germany.
Peter KraftDepartment of Neurology, University Hospital Würzburg, 97080 Würzburg, Germany.
Thorsten F KrugDepartment of Neurology, Clinic of Neurology and Institute for Translational Neurology, University of Münster, 48149 Münster, Germany.
Johanna BreuerDepartment of Neurology, Clinic of Neurology and Institute for Translational Neurology, University of Münster, 48149 Münster, Germany.
Martin HeroldDepartment of Neurology, Clinic of Neurology and Institute for Translational Neurology, University of Münster, 48149 Münster, Germany.
Catharina C GrossDepartment of Neurology, Clinic of Neurology and Institute for Translational Neurology, University of Münster, 48149 Münster, Germany.
Denise BeckmannInstitute of Experimental Musculoskeletal Medicine, University Hospital Münster, 48149 Münster, Germany.
Adelheid Korb-PapInstitute of Experimental Musculoskeletal Medicine, University Hospital Münster, 48149 Münster, Germany.
Michael K SchuhmannDepartment of Neurology, University Hospital Würzburg, 97080 Würzburg, Germany.
Stefanie KuertenDepartment of Anatomy and Cell Biology, University of Würzburg, 97070 Würzburg, Germany.
Ioannis MitroulisDepartment of Clinical Pathobiochemistry and Institute for Clinical Chemistry and Laboratory Medicine, University Clinic Carl Gustav Carus, Technische Universität of Dresden, 01307 Dresden, Germany.
Clemens RuppertDepartment of Internal Medicine, Universities of Giessen &Marburg Lung Center (UGMLC)/Member of the German Center for Lung Research (DZL), Justus-Liebig University, 35392 Giessen, Germany.
Marc W NolteCSL Behring GmbH, 35041 Marburg, Germany.
Con PanousisCSL Limited, Bio21 Institute, Parkville, Victoria 3010, Australia.
Luisa KlotzDepartment of Neurology, Clinic of Neurology and Institute for Translational Neurology, University of Münster, 48149 Münster, Germany.
Beate KehrelDepartment of Anesthesiology, Intensive Care and Pain Medicine, Experimental and Clinical Hemostasis, University of Münster, 48149 Münster, Germany.
Thomas KornDepartment of Neurology, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany.
Harald F LangerDepartment of Cardiology and Cardiovascular Medicine, Section for Cardioimmunology, University Clinic of Tübingen, 72076 Tübingen, Germany.
Thomas PapInstitute of Experimental Musculoskeletal Medicine, University Hospital Münster, 48149 Münster, Germany.
Bernhard NieswandtRudolf Virchow Center, Deutsche Forschungsgemeinschaft Research Center for Experimental Biomedicine, University of Würzburg, 97080 Würzburg, Germany.
Heinz WiendlDepartment of Neurology, Clinic of Neurology and Institute for Translational Neurology, University of Münster, 48149 Münster, Germany.
Triantafyllos ChavakisDepartment of Clinical Pathobiochemistry and Institute for Clinical Chemistry and Laboratory Medicine, University Clinic Carl Gustav Carus, Technische Universität of Dresden, 01307 Dresden, Germany.
Christoph KleinschnitzDepartment of Neurology, University Hospital Würzburg, 97080 Würzburg, Germany.
Sven G MeuthDepartment of Neurology, Clinic of Neurology and Institute for Translational Neurology, University of Münster, 48149 Münster, Germany.
University Hospital Münster · DEUniversity of Münster · DEUniversitätsklinikum Würzburg · DEUniversity Hospital Carl Gustav Carus · DEBehringwerke (Germany) · DECSL (Australia) · AUDeutsche Forschungsgemeinschaft · DEEssen University Hospital · DETechnical University of Munich · DEUniversities of Giessen and Marburg Lung Center · DEUniversity of Tübingen · DEUniversity of Würzburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aberrant immune responses represent the underlying cause of central nervous system (CNS) autoimmunity, including multiple sclerosis (MS). Recent evidence implicated the crosstalk between coagulation and immunity in CNS autoimmunity. Here we identify coagulation factor XII (FXII), the initiator of the intrinsic coagulation cascade and the kallikrein-kinin system, as a specific immune cell modulator. High levels of FXII activity are present in the plasma of MS patients during relapse. Deficiency or pharmacologic blockade of FXII renders mice less susceptible to experimental autoimmune encephalomyelitis (a model of MS) and is accompanied by reduced numbers of interleukin-17A-producing T cells. Immune activation by FXII is mediated by dendritic cells in a CD87-dependent manner and involves alterations in intracellular cyclic AMP formation. Our study demonstrates that a member of the plasmatic coagulation cascade is a key mediator of autoimmunity. FXII inhibition may provide a strategy to combat MS and other immune-related disorders.

Indexed as

Adaptive ImmunityAdultAgedAnimalsCell DifferentiationDendritic CellsEncephalomyelitis, Autoimmune, ExperimentalFactor XIIFemaleHumansInterleukin-17KallikreinsKininsMaleMice, Inbred C57BLMiddle AgedFactor XIIIl17a protein, mouseInterleukin-17KallikreinsKininsPlaur protein, mouseReceptors, Urokinase Plasminogen Activator

Identifiers

PMID27188843
PMCPMC4873982
OpenAlexW2402160868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.